Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver

Lipids in Health and Disease

Volumn 8, Issue , 2009, Pages

  Bighetti, Eliete J B ^a   Patrício, Patrícia R ^a   Casquero, Andrea C ^a   Berti, Jairo A ^a   Oliveira, Helena C F ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; FATTY ACID; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; CLOFIBRIC ACID; DRUG DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEMALE; GENE EXPRESSION; GENOTYPE; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; GENETICS; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

MUS;

ANIMALS; APOLIPOPROTEIN C-III; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CLOFIBRIC ACID; GENE EXPRESSION; HYPERTRIGLYCERIDEMIA; LIVER; MICE; PPAR ALPHA;

EID: 72449204162     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-8-50     Document Type: Article

References (51)

1. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. WJ McConathy JC Gesquiere H Bass A Tartar JC Fruchart CS Wang, J Lipid Res 1992 33 995 1003 1431591
2. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. E Sehayek S Eisenberg, J Biol Chem 1991 266 18259 18267 1917954
3. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. T Ebara R Ramakrishnan G Steiner NS Shachter, J Clin Invest 1997 99 2672 2681 10.1172/JCI119456 9169497
4. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Y Ito N Azrolan A O'Connell A Walsh JL Breslow, Science 1990 249 790 793 10.1126/science.2167514 2167514
5. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. FM Sacks P Alaupovic LA Moye TG Cole B Sussex MJ Stampfer MA Pfeffer E Braunwald, Circulation 2000 102 1886 1892 11034934
6. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. P Alaupovic WJ Mack C Knight-Gibson HN Hodis, Arterioscler Thromb Vasc Biol 1997 17 715 722 9108785
7. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. SJ Lee H Campos LA Moye FM Sacks, Arterioscler Thromb Vasc Biol 2003 23 853 858 10.1161/01.ATV.0000066131.01313.EB 12637336
8. -1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. AR Tall X Jiang Y Luo D Silver, Arterioscler Thromb Vasc Biol 2000 20 1185 1188 10807731
9. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. PJ Barter HB Brewer Jr MJ Chapman CH Hennekens DJ Rader AR Tall, Arterioscler Thromb Vasc Biol 2003 23 160 167 10.1161/01.ATV.0000054658.91146.64 12588754
10. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? H Neeli DJ Rader, Cardiol Clin 2008 26 537 546 10.1016/j.ccl.2008.06.005 18929230
11. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. A Thompson E Di Angelantonio N Sarwar S Erqou D Saleheen RP Dullaart B Keavney Z Ye J Danesh, JAMA 2008 23 2777 2788 10.1001/jama.299.23.2777 (Pubitemid 351846853)
12. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. S Zhong DS Sharp JS Grove C Bruce K Yano JD Curb AR Tall, J Clin Invest 1996 97 2917 2923 10.1172/JCI118751 8675707
13. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. C Harder P Lau A Meng SC Whitman R McPherson, Arterioscler Thromb Vasc Biol 2007 27 858 864 10.1161/01.ATV.0000259357.42089.dc 17272756
14. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. M Westerterp CC van der Hoogt W de Haan EH Offerman GM Dallinga-Thie JW Jukema LM Havekes PC Rensen, Arterioscler Thromb Vasc Biol 2006 26 2552 2559 10.1161/01.ATV. 0000243925.65265.3c 16946130
15. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. KR Marotti CK Castle TP Boyle AH Lin RW Murray GW Melchior, Nature 1993 364 73 75 10.1038/364073a0 8316302
16. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. PM Cazita JA Berti C Aoki M Gidlund LM Harada VS Nunes EC Quintao HC Oliveira, J Lipid Res 2003 44 33 40 10.1194/jlr.M100440-JLR200 12518020
17. Effects of diabetes and CETP expression on diet-induced atherosclerosis in LDL receptor-deficient mice. JA Berti AG Salerno EJ Bighetti AC Casquero AC Boschero HC Oliveira, APMIS 2005 113 37 44 10.1111/j.1600-0463.2005.apm1130106.x 15676013
18. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. J Auwerx K Schoonjans JC Fruchart B Staels, Atherosclerosis 1996 124 Suppl 29 37 10.1016/0021-9150(96)05854-6 8831913
19. Mechanism of action of fibrates on lipid and lipoprotein metabolism. B Staels J Dallongeville J Auwerx K Schoonjans E Leitersdorf JC Fruchart, Circulation 1998 98 2088 2093 9808609
20. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. A Gnasso B Lehner W Haberbosch O Leiss K von Bergmann J Augustin, Metabolism 1986 35 387 393 10.1016/0026-0495(86)90125-3 3458020
21. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. L Berthou N Duverger F Emmanuel S Langouet J Auwerx A Guillouzo JC Fruchart E Rubin P Denefle B Staels D Branellec, J Clin Invest 1996 97 2408 2416 10.1172/JCI118687 8647932
22. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. N Vu-Dac S Chopin-Delannoy P Gervois E Bonnelye G Martin JC Fruchart V Laudet B Staels, J Biol Chem 1998 273 25713 25720 10.1074/jbc.273.40.25713 9748239
23. Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. M Bouly D Masson B Gross XC Jiang C Fievet G Castro AR Tall JC Fruchart B Staels L Lagrost G Luc, J Biol Chem 2001 276 25841 25847 10.1074/jbc.M101160200 11342537
24. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome. GF Watts J Ji DC Chan EM Ooi AG Johnson KA Rye PH Barrett, Clin Sci (Lond) 2006 111 193 199 Erratum in: Clin Sci (Lond) 2007, 112 :625 10.1042/CS20060072 16700661
25. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. PN Durrington MI Mackness D Bhatnagar K Julier H Prais S Arrol J Morgan GN Wood, Atherosclerosis 1998 138 217 225 10.1016/S0021-9150(98)00003-3 9678787
26. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. M Guerin E Bruckert PJ Dolphin G Turpin MJ Chapman, Arterioscler Thromb Vasc Biol 1996 16 763 772 8640404
27. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. IJ Jonkers AH Smelt H Hattori LM Scheek T van Gent FH de Man A van der Laarse A van Tol, J Lipid Res 2003 44 1462 1469 10.1194/jlr.M300008-JLR200 12754275
28. Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy. R McPherson G Agnani P Lau JC Fruchart AD Edgar YL Marcel, Arterioscler Thromb Vasc Biol 1996 16 1340 1346 8911272
29. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. CJ Mann FT Yen AM Grant BE Bihain, J Clin Invest 1991 88 2059 2066 10.1172/JCI115535 1752964
30. Mechanism of the gemfibrozil-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins. G Ponsin G Girardot F Berthezene, Biochem Med Metab Biol 1994 52 58 64 10.1006/bmmb.1994.1034 7917468
31. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. G Franceschini MR Lovati C Manzoni S Michelagnoli F Pazzucconi G Gianfranceschi G Vecchio CR Sirtori, Atherosclerosis 1995 114 61 71 10.1016/0021-9150(94)05465-U 7605377
32. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. J Kahri T Sane A van Tol MR Taskinen, J Intern Med 1995 238 429 436 10.1111/j.1365-2796.1995.tb01220.x 7595182
33. Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein. TP Beyer Y Chen RK Porter D Lu RJ Schmidt NB Mantlo RJ Konrad G Cao, Lipids 2008 43 611 618 10.1007/s11745-008-3187-0 18481130
34. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. CC van der Hoogt W de Haan M Westerterp M Hoekstra GM Dallinga-Thie JA Romijn HM Princen JW Jukema LM Havekes PC Rensen, J Lipid Res 2007 48 1763 1771 10.1194/jlr.M700108-JLR200 17525476
35. Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. XC Jiang LB Agellon A Walsh JL Breslow A Tall, J Clin Invest 1992 90 1290 1295 10.1172/JCI115993 1401066
36. Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3' to the gene in the promoter of the adjacent convergently transcribed apoC-III gene. A Walsh N Azrolan K Wang A Marcigliano A O'Connell JL Breslow, J Lipid Res 1993 34 617 623 8496667
37. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice. JA Berti ME Amaral AC Boschero VS Nunes LM Harada LN Castilho HC Oliveira, Metabolism 2001 50 530 536 10.1053/meta.2001.22514 11319713
38. Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. S Jiao TG Cole RT Kitchens B Pfleger G Schonfeld, Metabolism 1990 39 155 160 10.1016/0026-0495(90)90069-O 2299988
39. A method for the simultaneous measurement of insulin release and B cell membrane potential in single mouse islets of Langerhans. AM Scott I Atwater E Rojas, Diabetologia 1981 21 470 475 10.1007/BF00257788 7028561
40. Preparation, characterization, and measurement of hepatic lipase. C Ehnholm T Kuusi, Methods Enzymol 1986 129 716 738 full-text 3724551
41. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia. Relation to cholesteryl ester transfer protein activity and other lipoprotein variables. R McPherson CJ Mann AR Tall M Hogue L Martin RW Milne YL Marcel, Arterioscler Thromb 1991 11 797 804 2065034
42. 'In vitro' cholesteryl ester bidirectional flow between high-density lipoproteins and triglyceride-rich emulsions: effects of particle concentration and composition, cholesteryl ester transfer activity and oleic acid. HC Oliveira EC Quintao, J Biochem Biophys Methods 1996 32 45 57 10.1016/0165-022X(94)00060- Q 8773547
43. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. MM Tai, Diabetes Care 1994 17 152 154 10.2337/diacare.17.2.152 8137688
44. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. S Eisenberg D Gavish Y Oschry M Fainaru RJ Deckelbaum, J Clin Invest 1984 74 470 482 10.1172/JCI111444 6378975
45. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. RC Pasternak LE Brown PH Stone DI Silverman CM Gibson FM Sacks, Ann Intern Med 1996 125 529 540 8815751
46. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias. G Turpin E Bruckert, Atherosclerosis 1996 124 Suppl 83 87 10.1016/0021-9150(96)05861-3 8831920
47. Down-regulation of hepatic lipase gene expression and activity by fenofibrate. B Staels J Peinado-Onsurbe J Auwerx, Biochim Biophys Acta 1992 1123 227 230 1739751
48. Streptozotocin-induced increase in cholesterol ester transfer protein (CETP) and its reversal by insulin in transgenic mice expressing human CETP. SK Cheema F Rashid-Kolvear, Can J Physiol Pharmacol 2003 81 997 1004 10.1139/y03-093 14608418
49. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. Y Luo AR Tall, J Clin Invest 2000 105 513 520 10.1172/JCI8573 10683381
50. Decreased affinity of low density lipoprotein (LDL) particles for LDL receptors in patients with cholesteryl ester transfer protein deficiency. N Sakai S Yamashita K Hirano M Ishigami T Arai K Kobayashi T Funahashi Y Matsuzawa, Eur J Clin Invest 1995 25 332 339 10.1111/j.1365-2362.1995.tb01710.x 7628520
51. Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice. P Mardones A Pilon M Bouly D Duran T Nishimoto H Arai KF Kozarsky M Altayo JF Miquel G Luc V Clavey B Staels A Rigotti, Biol Chem 2003 278 7884 7890 10.1074/jbc.M211627200 (Pubitemid 36800523)